BofA analyst Alex Stranahan raised the firm’s price target on Revolution Medicines (RVMD) to $185 from $170 and keeps a Buy rating on the shares. The Q1 report “largely reinforced what we’d characterize as best-case RASolute 302 data” ahead of the full presentation at ASCO, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $205 from $175 at Guggenheim
- Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial
- Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)
- Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B
- Revolution Medicines announces NEJM publication of data on Daraxonrasib